Perception Neuroscience Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ketamine fueled actor Matthew Perry s death, but new study says it may help others

Ketamine fueled actor Matthew Perry s death, but new study says it may help others
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Wendy lynchMatthew perryPsychonaught wikipediaPerception neuroscience incBrain instituteA university of virginiaNeurobehavioral sciencesSchool of medicine department psychiatryPerception neuroscience

Research: Ketamine, Linked to Perry s Death, May Aid Others

Research: Ketamine, Linked to Perry s Death, May Aid Others
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Wendy lynchPerception neuroscience incSchool of medicine department psychiatryBrain instituteNeurobehavioral sciencesPerception neuroscience

atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

NEW YORK and BERLIN, April 13, 2023(NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has

New yorkUnited statesAllan malievskyStephen bardinHercules capital incLife sciencesExchange commissionPerception neuroscience incSecurities exchangePerception neurosciencePrivate securities litigation reform actSecurities actSecurities exchange actHercules capitalFinancial conditionExternal affairs

Investegate |atai Life Sciences Announcements | atai Life Sciences: atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

Investegate announcements from atai Life Sciences, atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

New yorkUnited statesAllan malievskyStephen bardinSecurities exchangePerception neuroscience incExchange commissionLife sciences announces first subjectLife sciencesHercules capital incLife sciences announces first subject dosedSubcutaneous bridging studyPerception neurosciencePrivate securities litigation reform actSecurities actSecurities exchange act

Atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

NEW YORK and BERLIN, April 13, 2023 atai Life Sciences , a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first. | April 13, 2023

New yorkUnited statesAllan malievskyStephen bardinPerception neuroscience incGlobenewswire incExchange commissionSecurities exchangeHercules capital incLife sciencesPerception neurosciencePrivate securities litigation reform actSecurities actSecurities exchange actHercules capitalFinancial condition